Acoustic Characterization and Pharmacokinetic Analyses of New Nanobubble Ultrasound Contrast Agents

• Published in: Ultrasound in medicine & biology Vol. 39; no. 11; pp. 2137 - 2146
• Main Authors: Wu, Hanping, Rognin, Nicolas G, Krupka, Tianyi M, Solorio, Luis, Yoshiara, Hiroki, Guenette, Gilles, Sanders, Christopher, Kamiyama, Naohisa, Exner, Agata A
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.11.2013
• Subjects: Acoustics; Animals; Cancer; Fluorocarbons - chemistry; Fluorocarbons - pharmacokinetics; Materials Testing; Metabolic Clearance Rate; Mice; Mice, Nude; Nanobubble; Nanoparticles - chemistry; Organ Specificity; Phantoms, Imaging; Pharmacokinetic study; Poloxamer - chemistry; Poloxamer - pharmacokinetics; Radiology; Tissue Distribution; Ultrasonography - instrumentation; Ultrasonography - methods; Ultrasound contrast agents; Pharmacokinetic study; Nanobubble; Ultrasound contrast agents; Cancer
• ISSN: 0301-5629; 1879-291X
• DOI: 10.1016/j.ultrasmedbio.2013.05.007

Abstract In contrast to the clinically used microbubble ultrasound contrast agents, nanoscale bubbles (or nanobubbles) may potentially extravasate into tumors that exhibit more permeable vasculature, facilitating targeted molecular imaging and drug delivery. Our group recently presented a simple strategy using the non-ionic surfactant Pluronic as a size control excipient to produce nanobubbles with a mean diameter of 200 nm that exhibited stability and echogenicity on par with microbubbles. The objective of this study was to carry out an in-depth characterization of nanobubble properties as compared with Definity microbubbles, both in vitro and in vivo . Through use of a tissue-mimicking phantom, in vitro experiments measured the echogenicity of the contrast agent solutions and the contrast agent dissolution rate over time. Nanobubbles were found to be more echogenic than Definity microbubbles at three different harmonic frequencies (8, 6.2 and 3.5 MHz). Definity microbubbles also dissolved 1.67 times faster than nanobubbles. Pharmacokinetic studies were then performed in vivo in a subcutaneous human colorectal adenocarcinoma (LS174T) in mice. The peak enhancement and decay rates of contrast agents after bolus injection in the liver, kidney and tumor were analyzed. No significant differences were observed in peak enhancement between the nanobubble and Definity groups in the three tested regions (tumor, liver and kidney). However, the decay rates of nanobubbles in tumor and kidney were significantly slower than those of Definity in the first 200-s fast initial phase. There were no significant differences in the decay rates in the liver in the initial phase or in three regions of interest in the terminal phase. Our results suggest that the stability and acoustic properties of the new nanobubble contrast agents are superior to those of the clinically used Definity microbubbles. The slower washout of nanobubbles in tumors suggests potential entrapment of the bubbles within the tumor parenchyma.